Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics

Posted on
by

Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics
The Key Polycythemia Vera Companies:in the market include – Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others.

 

DelveInsight’s report, “Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Polycythemia Vera landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

 

Additionally, it examines Polycythemia Vera market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

 

To Know in detail about the Polycythemia Vera market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polycythemia Vera Market Forecast

 

Some of the key facts of the Polycythemia Vera Market Report:

  • The total Polycythemia Vera market size across the 7MM is estimated at around USD 2,000 million in 2025 and is expected to grow steadily over the forecast period from 2026 to 2036.

  • In March 2026, A Phase 2 trial evaluating oral epetraborole in polycythemia vera (PV) is anticipated to commence in the third quarter of 2026, with initial data readouts expected as early as the fourth quarter of 2026 and continuing into 2027.

  • In January 2026, A New Drug Application (NDA) has been filed with the FDA requesting approval of rusfertide for the treatment of adults with polycythemia vera (PV). The submission is supported by results from the Phase III VERIFY trial (NCT05210790) and the Phase II REVIVE trial (NCT04057040). Findings from Part 1a of the VERIFY study indicated that rusfertide, a first-in-class hepcidin mimetic, achieved the primary endpoint along with all four key secondary endpoints, demonstrating sustained hematocrit control and significantly reducing the need for phlebotomy.

  • In November 2025, SOTIO Biotech, a clinical-stage biopharmaceutical company under the PPF Group, announced encouraging preclinical findings for its antibody-drug conjugate SOT106 for sarcoma treatment, presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting in November.

  • In August 2025, The FDA has awarded Breakthrough Therapy Designation to rusfertide, a first-in-class hepcidin-mimetic peptide, for treating erythrocytosis in polycythemia vera (PV) patients with limited therapeutic options to reduce phlebotomy needs and improve blood count control. This designation was based on promising results from the Phase 3 VERIFY trial (NCT05210790), which compared rusfertide plus standard of care (SOC) against placebo plus SOC. In the 32-week analysis presented at the 2025 ASCO Annual Meeting, 76.9% of patients on rusfertide plus SOC (n=147) achieved a response between weeks 20 and 32, compared with 32.9% of those on placebo plus SOC (n=146; P < .0001).

  • In August 2025, Vanda Pharmaceuticals revealed that the FDA has awarded Orphan Drug Designation to VGT-1849B, a JAK2 inhibitor, for the treatment of polycythemia vera (PV).

  • In August 2025, Protagonist Therapeutics’ rusfertide has been granted FDA Breakthrough Therapy Designation for the treatment of erythrocytosis in polycythemia vera, backed by encouraging Phase 3 VERIFY trial results presented at ASCO 2025.

  • In May 2025, The FDA granted Fast Track designation to givinostat (Duvyzat) for the treatment of polycythemia vera, according to a press release from its developer, Italfarmaco. Previously, givinostat received orphan drug designation for the same indication from both the FDA and the European Medicines Agency (EMA). Additionally, the drug has been approved by the FDA and the UK’s Medicines and Healthcare Products Regulatory Agency for the treatment of Duchenne muscular dystrophy.

  • In March 2025, Protagonist Therapeutics, Inc. (NASDAQ: PTGX) and Takeda (TSE: 4502/NYSE: TAK) have announced positive topline results from the Phase 3 VERIFY study. The trial involved phlebotomy-dependent polycythemia vera (PV) patients, who were randomly assigned to receive either rusfertide or a placebo alongside standard care. The study successfully achieved its primary endpoint along with all four key secondary endpoints. Rusfertide, an investigational first-in-class hepcidin mimetic peptide therapeutic, has been granted Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA).

  • In 2025, the United States accounted for the largest share of the Polycythemia Vera market among the 7MM, with an estimated value of around USD 1,500 million, and this figure is expected to grow further by 2036, driven by the introduction of emerging therapies and a rising diagnosed patient population.

  • Within the EU4 and the UK, Germany held the highest market share in 2025, while the United Kingdom represented the smallest market.

  • In 2025, among the available treatments for Polycythemia Vera, JAKAFI generated the highest revenue in the United States, at approximately USD 1,000 million.

  • Looking ahead to 2036, among the emerging therapies in the EU4 and the UK, Rusfertide is projected to achieve the highest revenue.

  • The primary approach to managing Polycythemia Vera continues to be phlebotomy to control hematocrit levels, typically used alongside low-dose aspirin. For high-risk patients, cytoreductive treatments such as hydroxycarbamide (hydroxyurea) may also be administered.

  • Jakafi and BESREMi are approved across the US, Europe, and Japan, with Jakafi serving as a standard second-line therapy since 2015. Additionally, PEGASYS received marketing authorization in 2024 and formal approval in the UK in 2025, following its earlier off-label use.

  • In 2025, the United States accounted for the largest share of the prevalent Polycythemia Vera population, representing approximately 55% of cases across the 7MM. In comparison, the EU4 and the UK contributed around 30%, while Japan accounted for about 15% of the total share.

  • The number of prevalent cases in the United States was estimated at approximately 158,700 in 2025. Among the EU4 and the UK, Germany reported the highest number of cases based on symptoms, whereas the United Kingdom had the lowest in 2025.

  • According to DelveInsight estimates, the United States reported approximately 63,000 asymptomatic and 95,000 symptomatic cases of Polycythemia Vera in 2025, with overall prevalence expected to rise during the forecast period.

  • Across the 7MM, around 60% of Polycythemia Vera cases are observed in males, while females account for approximately 40% of the patient population.

  • In Japan, age-specific data indicate that the highest number of cases occurs in the 65–74 age group, with about 6,000 cases in 2025, whereas the lowest incidence is seen among individuals aged 0–34 years, with roughly 800 cases.

  • Other investigational therapies for Polycythemia Vera include bomedemstat (an LSD1 inhibitor by Merck), sapablursen (a TMPRSS6 inhibitor developed by Ionis Pharmaceuticals in collaboration with Ono Pharmaceutical), divesiran (a TMPRSS6 inhibitor from Silence Therapeutics), PPMX-T003 (an anti-TfR1 therapy by Perseus Proteomics), and DISC-3405 (an anti-TMPRSS6 agent from Disc Medicine), among others—underscoring a rapidly expanding and innovative treatment pipeline.

  • Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others

  • Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others

  • The Polycythemia Vera epidemiology based on gender analyzed that mostly males are affected in case of Polycythemia Vera

  • The Polycythemia Vera market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polycythemia Vera pipeline products will significantly revolutionize the Polycythemia Vera market dynamics.

 

Polycythemia Vera Overview

Polycythemia vera (PV) is a rare and chronic blood disorder characterized by the overproduction of red blood cells in the bone marrow. This excess production of red blood cells leads to an increase in blood volume and thickness, which can cause complications such as blood clots, stroke, or heart attack. PV is a type of myeloproliferative neoplasm, a group of disorders in which the bone marrow produces too many blood cells.

 

Get a Free sample for the Polycythemia Vera Market Report:

https://www.delveinsight.com/report-store/polycythemia-vera-market

 

Polycythemia Vera Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Polycythemia Vera Epidemiology Segmentation:

The Polycythemia Vera market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Polycythemia Vera

  • Prevalent Cases of Polycythemia Vera by severity

  • Gender-specific Prevalence of Polycythemia Vera

  • Diagnosed Cases of Episodic and Chronic Polycythemia Vera

 

Download the report to understand which factors are driving Polycythemia Vera epidemiology trends @ Polycythemia Vera Epidemiology Forecast

 

Polycythemia Vera Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polycythemia Vera market or expected to get launched during the study period. The analysis covers Polycythemia Vera market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Polycythemia Vera Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Polycythemia Vera Therapies and Key Companies

  • Rusfertide (PTG-300): Protagonist Therapeutics

  • Givinostat (ITF2357): Italfarmaco

  • Bomedemstat: Imago BioSciences

  • SLN124: Silence Therapeutics

  • Sapablursen: Ionis Pharmaceutical

  • PPMX-T003: Perseus Proteomics

  • PTG-300: Protagonist Therapeutics, Inc.

  • SLN124: Silence Therapeutics plc

  • Hydroxyurea: Novartis

  • Ropeginterferon alfa-2b: PharmaEssentia

  • PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG

  • Ruxolitinib: Incyte Corporation

 

Discover more about therapies set to grab major Polycythemia Vera market share @ Polycythemia Vera Treatment Market

 

Polycythemia Vera Market Strengths

  • The approval of BESREMi in the US and its expected approval in Japan, in both the first and second line of treatment, provides the interferon with an immense opportunity to garner a big market size in Polycythemia Vera.

  • Based on increasing sales of JAKAFI/JAKAVI, the drug will be a blockbuster therapy in 2L PV patients.

 

Polycythemia Vera Market Opportunities

  • An increase in strategic alliances, such as geographical alliances, and granting the designation such as BTD and FTD by the FDA are some of the factors that will drive the market growth.

  • Opportunity for drugs with novel and disease-modifying mechanisms and low side effect.

 

Scope of the Polycythemia Vera Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others

  • Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others

  • Polycythemia Vera Therapeutic Assessment: Polycythemia Vera current marketed and Polycythemia Vera emerging therapies

  • Polycythemia Vera Market Dynamics: Polycythemia Vera market drivers and Polycythemia Vera market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Polycythemia Vera Unmet Needs, KOL’s views, Analyst’s views, Polycythemia Vera Market Access and Reimbursement

 

To know more about Polycythemia Vera companies working in the treatment market, visit @ Polycythemia Vera Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Polycythemia Vera Market Report Introduction

2. Executive Summary for Polycythemia Vera

3. SWOT analysis of Polycythemia Vera

4. Polycythemia Vera Patient Share (%) Overview at a Glance

5. Polycythemia Vera Market Overview at a Glance

6. Polycythemia Vera Disease Background and Overview

7. Polycythemia Vera Epidemiology and Patient Population

8. Country-Specific Patient Population of Polycythemia Vera

9. Polycythemia Vera Current Treatment and Medical Practices

10. Polycythemia Vera Unmet Needs

11. Polycythemia Vera Emerging Therapies

12. Polycythemia Vera Market Outlook

13. Country-Wise Polycythemia Vera Market Analysis (2020–2034)

14. Polycythemia Vera Market Access and Reimbursement of Therapies

15. Polycythemia Vera Market Drivers

16. Polycythemia Vera Market Barriers

17. Polycythemia Vera Appendix

18. Polycythemia Vera Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/